Clenoliximab

N/A

Report date: 2022/02/10 11:24:51

Base Information

Drug NameClenoliximab
Drug Alias NamePRIMATIZED anti-CD4 antibody IDEC 151Anti-CD4 monoclonal antibody IDEC 151SB-217969IDEC 151
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionT-cell surface antigen CD4 inhibitors
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsPsoriasisAsthmaArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen (Denmark) A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen (Denmark) A/S
Active IndicationsN/A
Inactive IndicationsPsoriasisAsthmaArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank